Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer.

7547 Background: 1st-line tyrosine kinase inhibitor (TKI) therapy for patients (pts) with EGFR-mutant lung cancer prolongs progression free survival (PFS) and improves quality of life. When pts dev...